Three-Year Follow-up of Sirolimus-Eluting Stents vs. Bare Metal Stents for Acute Myocardial Infarction

Ejiri, Kentaro; Ishihara, Masaharu; Dai, Kazuoki; Miki, Takashi; Inoue, Ichiro; Kawagoe, Takuji; Sakai, Yuji; Miura, Fumiharu; Nakama, Yasuharu; Otani, Takayuki; Ikenaga, Hiroki; Oda, Nozomu; Nakamura, Masayuki

doi:10.1253/circj.cj-11-0300

Cited by 13 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The variables are as described in Table 1 T. Miyamoto et al placement compared with that after SES placement [18] did not relate to the higher incidence of definite VLST during several years. Thus, although the duration of DAPT was not fully understood in the present retrospective and nonrandomized study, this study is the first to indicate the equivalent frequency of severe clinical cardiac outcomes of first-generation DES for STEMI patients with the longest interval compared with those in the previous reports in Japan [1][2][3][4]6]. Although SESs and PESs are not available at present, the present study would be useful for anticipating the outcomes of patients continuously treated at outpatients with first-generation DESs.…”

Section: Discussionmentioning

confidence: 69%

“…The long-term safety and efficacy of sirolimus-eluting stents (SESs; Cypher Bx Velocity; Cordis Corp., Miami, FL, USA) for use in primary stenting in patients with STelevation myocardial infarction (STEMI) in comparison with those of bare-metal stents (BMSs) have been established in Japan [1][2][3][4] (Ref. [1]: mean follow-up for SES, 1327 ± 415 days; for BMS, 1818 ± 681 days).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Miyamoto

Ishikawa

Nakano

et al. 2016

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

We conducted a retrospective examination of the very long-term outcomes of placing sirolimus (SES) and paclitaxel (PES)-eluting stents in patients with ST-elevation myocardial infarction (STEMI). This was a nonrandomized, retrospective, single-center study that included 872 first STEMI patients who underwent successful placement of either SES (n = 547) or PES from November 2004 to April 2012. The primary end point was the incidence of severe cardiac events comprising cardiac death, nonfatal recurrent myocardial infarction, and definite stent thrombosis (ST). The frequency of target lesion revascularization (TLR) was also compared. A propensity score-matched analysis was used to adjust the 29 baseline variables. In the baseline-adjusted cohorts in 231 STEMI patients in each arm, the frequency of the primary end point in the SES group (5.6 %) during the follow-up duration of 2583 ± 806 days was not significantly different from that in the PES group (6.1 %, follow-up: 1866 ± 699 days). The cumulative primary end point-free ratio in the SES group was not significantly different from that in the PES group (p = 0.503). The frequency of TLR in the SES group (7.5 %) was significantly lower than that in the PES group (16.9 %, p = 0.005), with and the significantly higher cumulative TLR-free ratio in the SES group than that in the PES group (p < 0.001). The very long-term clinical outcomes after SES or PES placement for STEMI patients were statistically equivalent. SES showed the better angiographic outcomes for STEMI compared to PES.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Introductionmentioning

confidence: 99%

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Miyamoto

Ishikawa

Nakano

et al. 2016

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

show abstract

Potential cardiovascular applications of glutamate, aspartate, and other amino acids

Arsenian¹

1998

Clinical Cardiology

View full text Add to dashboard Cite

Summary: Cardioplegic solutions rich in the hydrophilic, basic amino acids, glutamate and aspartate, have enhanced myocardial preservation and left ventricular function. This has been demonstrated in assorted animal preparations involving ischemia with and without reperfusion. Published clinical data. though limited, strongly support the contention that these amino acids have myocardial protective properties. Several biochemical mechanisms exist by which certain amino acids may attenuate ischemic or reperfusion injury. Glutamate and aspartate may become preferred myocardial fuels in the setting of ischemia. They may also reduce myocardial ammonia production and reduce cytoplasmic lactate levels, thereby deinhibiting glycolysis. Some amino acids may become substrate for the citric acid cycle. Glutamate and aspartate also move reducing equivalents from cytoplasm to mitochondria where they are necessary for oxidative phosphorylation and energy generation. A rationale exists for the use of an amino acid-rich cardioplegia-like solution in myocardial infarction. These solutions are safe and inexpensive.

show abstract

Midterm outcomes of bare-metal stenting after primary stenting for ST-segment elevated myocardial infarctions in the drug-eluting stent era: a propensity score-matched comparison with sirolimus-eluting stent

Nakata

Ishikawa

Nakano

et al. 2014

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

We performed a propensity score-matching comparison of the midterm clinical and angiographic outcomes after primary stenting between using bare-metal stents (BMSs) and sirolimus-eluting stent (SES; Cypher Bx Velocity) for ST-segment elevated myocardial infarction (STEMI), because, in the drug-eluting stent era, the indication of the BMSs when a large balloon diameter is required remained to be controversial. This was a single-center, nonrandomized, retrospective study investigated in October 2013 by enrolling STEMI patients treated with primary stenting using either SES (n = 468) or BMS (n = 171) between September 2004 and December 2011. In 204 patients, the baseline-adjusted values produced similar mean maximum balloon sizes (BMS 3.67 ± 0.47 mm; SES 3.70 ± 0.56 mm; p = 0.477), and the incidence rates of binary in-stent restenosis (% diameter stenosis >50 % on secondary angiography) after SES placement (7.8 %) was significantly lower than that after BMS placement (23.5 %; p = 0.002). In baseline-adjusted 300 patients, the incidence of the clinical endpoints comprising cardiac death, nonfatal recurrent MI, and definite stent thrombosis after SES placement (11.3 %; 1241 ± 786 days; p = 0.557) was not significantly different from after BMS placement (8.7 %; mean follow-up period, 549 ± 486 days; p = 0.557). SES was not significantly related to the clinical endpoint [hazard ratio 2.31; 95 % confidence interval (CI) 0.88-6.08; p = 0.089). BMS did not offset the SES's angiographic efficacy for primary stenting for STEMI patients, despite placed using a large-sized balloon.

show abstract

Three-Year Follow-up of Sirolimus-Eluting Stents vs. Bare Metal Stents for Acute Myocardial Infarction

Cited by 13 publications

References 35 publications

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

Potential cardiovascular applications of glutamate, aspartate, and other amino acids

Midterm outcomes of bare-metal stenting after primary stenting for ST-segment elevated myocardial infarctions in the drug-eluting stent era: a propensity score-matched comparison with sirolimus-eluting stent

Contact Info

Product

Resources

About